Meeting Coverage

Palliative care and coping in patients with acute myeloid leukemia receiving intensive induction therapy: A mediation analysis of data from a randomized trial.   Integrated palliative and oncology care (IPC) as part of...

Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with...

Evidence indicates that balancing treatment efficacy with complication risk is critically important for older adults with non-Hodgkin’s lymphoma (NHL); however, the survival outcomes, rates of toxicities, and healthcare...

Although previous studies suggest positive outcomes with novel salvage therapies for patients with relapsed/refractory classic Hodgkin’s lymphoma who are eligible for autologous stem cell transplant, the efficacies and outcomes...

Prior research indicates that survivors of non-Hodgkin’s lymphoma are at increased risk of secondary malignancies. However, data are lacking on long-term risk and whether such risk differs by treatment modality. Investigators...

To determine whether a correlation exists between baseline tumor burden and early tumor progression based on imaging in patients with diffuse large B-cell lymphoma (DLBCL) and Hodgkin’s lymphoma (HL), researchers analyzed...

With limited data on the real-world treatment of follicular lymphoma in a contemporary cohort of patients, researchers examined treatment patterns and outcomes among nearly 2,400 adult patients with an initial follicular...

Immunotherapy (IO) + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic non-small cell lung cancer (NSCLC), with IO-only therapy approved only for PD-L1+ NSCLC. Patients with PD-L1 scores from...

Survival outcomes for patients with adenosquamous carcinoma of the lung are not well understood by virtue of reduced prevalence. To address this, a recent study sought to compare the long-term survival among patients with...

Testing for mutations in BRCA1 and BRCA2 is recommended for all women with ovarian cancer, given important implications for treatment and prognosis. Despite this recommendation, studies show that only a small percentage of...

Although ovarian cancer is the third most common Lynch syndrome (LS)-associated cancer in women, there is no established screening strategy to identify LS in this population. It is hypothesized that an adequate family history...

Disparities in the adherence to National Comprehensive Cancer Network (NCCN) guideline-directed treatment and socioeconomic characteristics may be responsible for the differences in ovarian cancer outcomes of ovarian cancer in...

The National Cancer Institute (NCI) Framework for patient-centered communication (PCC) in Cancer Care highlights the potential of PCC to improve health-related quality of life (HRQoL), but to date, few studies have empirically...